Advertisement
Advertisement
U.S. markets open in 9 hours 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.90+0.40 (+4.71%)
At close: 04:00PM EDT
8.82 -0.08 (-0.90%)
After hours: 07:46PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.50
Open8.70
Bid8.74 x 1300
Ask9.00 x 1400
Day's Range8.50 - 8.99
52 Week Range7.61 - 19.99
Volume3,294,451
Avg. Volume5,026,776
Market Cap1.652B
Beta (5Y Monthly)2.34
PE Ratio (TTM)N/A
EPS (TTM)-1.03
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.45
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BCRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioCryst Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/26/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • American City Business Journals

    FDA makes partial clinical hold official for Durham firm's drug candidate

    The move by the FDA comes after the company voluntarily paused enrollment in multiple clinical trials over concerns about potential kidney dysfunction in patients.

  • GlobeNewswire

    BioCryst to Present at Upcoming Investor Conferences

    RESEARCH TRIANGLE PARK, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences: The Bank of America Securities 2022 Healthcare Conference in Las Vegas, NV on Tuesday, May 10, 2022, at 11:00 a.m. ET. The RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 18, 2022 at 1:35 p.m. ET.The H.C. Wainwright Global Investment Conference – pre-recorded fireside chat available

  • Motley Fool

    Why BioCryst Stock Lost Nearly 4% of Its Value Today

    The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.

Advertisement
Advertisement